Last Updated: July 28, 2026

NUTRACORT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nutracort patents expire, and what generic alternatives are available?

Nutracort is a drug marketed by Bausch, Healthpoint, and Dow Pharm. and is included in four NDAs.

The generic ingredient in NUTRACORT is hydrocortisone. There are sixty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the hydrocortisone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nutracort

A generic version of NUTRACORT was approved as hydrocortisone by IMPAX LABS INC on March 30th, 2007.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for NUTRACORT?
  • What are the global sales for NUTRACORT?
  • What is Average Wholesale Price for NUTRACORT?
Summary for NUTRACORT
Recent Clinical Trials for NUTRACORT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
Children's Oncology GroupPhase 1
EsPhALL network I-BFM Study GroupPhase 3

See all NUTRACORT clinical trials

US Patents and Regulatory Information for NUTRACORT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch NUTRACORT hydrocortisone CREAM;TOPICAL 080442-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Dow Pharm NUTRACORT hydrocortisone LOTION;TOPICAL 080443-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bausch NUTRACORT hydrocortisone CREAM;TOPICAL 080442-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Healthpoint NUTRACORT hydrocortisone GEL;TOPICAL 084698-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Dow Pharm NUTRACORT hydrocortisone LOTION;TOPICAL 087644-001 Aug 24, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Dow Pharm NUTRACORT hydrocortisone LOTION;TOPICAL 080443-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for NUTRACORT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Takeda Pharmaceuticals International AG Ireland Branch Plenadren hydrocortisone EMEA/H/C/002185Treatment of adrenal insufficiency in adults. Authorised no no no 2011-11-03
Diurnal Europe B.V. Alkindi hydrocortisone EMEA/H/C/004416Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old). Authorised no no no 2018-02-09
Diurnal Europe B.V. Efmody hydrocortisone EMEA/H/C/005105Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults. Authorised no no no 2021-05-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal
Last updated: July 9, 2026

NUTRACORT market dynamics and financial trajectory: sales drivers, revenue trend, exclusivity timeline, and generic risk

NUTRACORT’s market trajectory is defined by a narrow commercial footprint, pricing pressure from local competitors and generics, and lifecycle risk concentrated in (1) formulation and method-of-use exclusivity, (2) OTC-to-Rx adjacency dynamics where applicable, and (3) regional approval status that determines when generic entry becomes legally and operationally feasible. A reliable financial trajectory analysis requires verified product scope (strength, dosage form), geography (US vs EU vs LATAM vs MENA), and current sales reporting. No such NUTRACORT-specific dataset is provided in the prompt, and an NUTRACORT-to-ingredient mapping is not supplied. Under the operating constraints, a complete and accurate market and financial trajectory cannot be produced.

What is NUTRACORT and how is it marketed in the current market?

Featured snippet answer: Insufficient verified product identity details to define the drug, active ingredient(s), strength, dosage form, and labeled indication set. Without those, market characterization and financial modeling cannot be made.

Which active ingredient and dosage form define NUTRACORT?

Featured snippet answer: Not provided.

Is NUTRACORT Rx-only, OTC, or mixed?

Featured snippet answer: Not provided.

What therapeutic class does NUTRACORT compete in?

Featured snippet answer: Not provided.

What patents protect NUTRACORT formulations, indications, and manufacturing?

Featured snippet answer: Not provided. Patent estate mapping requires the correct listed drug identity and jurisdictional filing record.

How many patents cover NUTRACORT and what are their expiration dates?

Featured snippet answer: Not provided.

What Orange Book status does NUTRACORT have (if US-listed)?

Featured snippet answer: Not provided.

Do method-of-use patents delay generic entry for NUTRACORT?

Featured snippet answer: Not provided.

When does NUTRACORT lose exclusivity and how much is runway before generic entry?

Featured snippet answer: Not provided.

What are the relevant exclusivity buckets (patent vs regulatory vs data exclusivity)?

Featured snippet answer: Not provided.

When do Paragraph IV challenges become legally available for NUTRACORT?

Featured snippet answer: Not provided.

Do settlements or consent judgments affect launch timing?

Featured snippet answer: Not provided.

Which companies sell competing products to NUTRACORT and how does market share shift?

Featured snippet answer: Not provided. Competitor sets depend on active ingredient, dosage form, route of administration, and geography.

How does NUTRACORT compete with branded vs generic corticosteroid/anti-inflammatory products (if relevant)?

Featured snippet answer: Not provided.

Are combination products or device-based formulations capturing share?

Featured snippet answer: Not provided.

What is the Orange Book status of NUTRACORT and what generic entry risks exist?

Featured snippet answer: Not provided.

What generic entry risks exist for NUTRACORT across routes and strengths?

Featured snippet answer: Not provided.

Do manufacturing/IP barriers (process, particle size, excipients, sterility) matter?

Featured snippet answer: Not provided.

What litigation affects NUTRACORT’s exclusivity and launch timelines?

Featured snippet answer: Not provided.

Which courts and case numbers involve NUTRACORT?

Featured snippet answer: Not provided.

Have any ANDA or biosimilar litigations been filed against NUTRACORT?

Featured snippet answer: Not provided.

How does NUTRACORT’s FDA regulatory status affect revenue trajectory (approvals, recalls, label changes)?

Featured snippet answer: Not provided. Regulatory status requires submission history, labeling events, and inspection/approval timelines.

What is the NUTRACORT approval path (505(b)(2), ANDA, NDA, supplement type)?

Featured snippet answer: Not provided.

Are there safety-driven label restrictions that limit prescribing?

Featured snippet answer: Not provided.

What are NUTRACORT’s revenue drivers and pricing dynamics (net sales, ASP, rebates, payer mix)?

Featured snippet answer: Not provided.

How do rebates, discounts, and payer contracting shape net sales?

Featured snippet answer: Not provided.

Does NUTRACORT face wholesale/retail inventory corrections that distort quarterly revenue?

Featured snippet answer: Not provided.

What is the typical gross margin profile for NUTRACORT in comparable markets?

Featured snippet answer: Not provided.

NUTRACORT financial trajectory: what do sales and growth trends show quarter by quarter?

Featured snippet answer: Not provided. Financial trajectory requires historical net sales data by geography and channel.

Which years show acceleration versus decline and why?

Featured snippet answer: Not provided.

How sensitive is NUTRACORT revenue to exclusivity erosion or competitor launches?

Featured snippet answer: Not provided.

What is the impact of supply disruptions or manufacturing scale changes?

Featured snippet answer: Not provided.

How does NUTRACORT compare with other drugs in the same category on exclusivity and pricing?

Featured snippet answer: Not provided. Category identification and comparable set require NUTRACORT’s active ingredient and market positioning.

Branded-to-generic conversion risk comparison

Featured snippet answer: Not provided.

Formulation lifecycle leverage comparison

Featured snippet answer: Not provided.

Competitive intensity comparison by geography

Featured snippet answer: Not provided.

Key Takeaways

No NUTRACORT-specific, verifiable product identity, jurisdictional regulatory status, exclusivity, patent estate, or historical sales dataset is included in the prompt. As required by the operating constraints, a complete and accurate market dynamics and financial trajectory cannot be produced.

FAQs

  1. Is NUTRACORT available in the US, and is it listed in the Orange Book?
  2. What is the NUTRACORT active ingredient and strength, and what does that imply for generic substitutability?
  3. What is the earliest date NUTRACORT could face generic entry based on patent or exclusivity expiry?
  4. Are there Paragraph IV challenges or consent settlements tied to NUTRACORT launches?
  5. Which competitors take share when NUTRACORT faces generic pricing pressure?

References (APA)

No sources were provided or cited in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.